Mizuho Rates uniQure (QURE) buy, $68 Price Target

Mizuho Reaffirms Rating on uniQure Stock

Mizuho has maintained its upbeat view on uniQure N.V. (NASDAQ:QURE). On June 25, 2026, analyst Uy Ear reiterated a buy rating on the shares and set a price target of $68. The update comes as Wall Street continues to monitor the biotechnology company's clinical pipeline and developmental treatments for rare genetic diseases.

uniQure Stock Performance and Moving Averages

uniQure shares trade around $47.51, reflecting solid momentum over the past year. The stock has posted a 52-week low of $8.73 and a high of $71.50. It currently trades well above its 50-day moving average of $40.20 and its 200-day moving average of $29.66. The company carries a market capitalization of roughly $1.56 billion and a beta of 1.06, indicating price swings in line with the broader market.

Analysts Set New Price Targets

Other Wall Street firms have adjusted their views on uniQure in recent months. On October 5, 2026, Barclays downgraded the stock to Equal-Weight and lowered its price target to $28 from $60. Days earlier, on October 2, 2026, RBC Capital maintained an Outperform rating while trimming its target from $65 to $48. Goldman Sachs kept a Neutral rating on September 30, 2026, adjusting its target to $31 from $46. Earlier in the summer, Wells Fargo maintained an Overweight rating with a $75 target on July 30, 2026, and Wolfe Research upgraded the stock to Outperform with a $65 target on the same day. Overall, the stock holds a strong buy consensus with a mean target price of $61.46 based on opinions from 12 analysts.

Inside uniQure's Biotechnology Pipeline

Headquartered in Amsterdam, the Netherlands, uniQure develops gene therapies for patients with rare and devastating conditions. Its commercial portfolio includes HEMGENIX, a treatment for hemophilia B that helps patients produce factor IX and reduces bleeding risks. The company's pipeline features AMT-130 in Phase I and II trials for Huntington's disease, alongside treatments for epilepsy, ALS, and Fabry disease. The company has no meaningful forward P/E ratio because it is not currently profitable, reporting an EPS of -4.03 and revenue of $18.67 million over the trailing period.

What to Watch Next for QURE

Investors are looking ahead to uniQure's next financial results, scheduled for release on November 9, 2026. Market participants will be watching for clinical trial updates on the company's gene therapy candidates and any further shifts in analyst price targets.